Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Attovia Therapeutics, Inc.. The associated price target remains the same with $45.00.

Sam Slutsky has given his Buy rating due to a combination of factors tied to Attovia’s clinical progress and financial strength. He highlights that early Phase 1b results for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis show compelling reductions in itch scores and meaningful improvements in disease severity, with durable IL-31 suppression supporting infrequent dosing and suggesting competitive differentiation versus existing biologics.

He also points to the company’s solid balance sheet, with over $115M in cash at quarter-end plus more than $300M in net IPO proceeds, providing funding visibility into 2030 and reducing financing risk through upcoming milestones. In addition, Attovia is preparing global Phase 2 trials in chronic pruritus of unknown origin and high-itch AD for the first half of 2027, which could serve as important value inflection points, and he maintains a $45 price target reflecting this favorable risk‑reward profile.

In another report released today, Morgan Stanley also assigned a Buy rating to the stock with a $39.00 price target.